Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | YWHAG | P61981 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927464 | 0.90 | PTGER1 (0.77) | PTGER1KMT2AALDH1A1NPC1LMNA | |
| SCHEMBL4925343 | 0.88 | PTGER1 (0.65) | PTGER1KMT2AALDH1A1ALOX15NPC1 | |
| SCHEMBL14008089 | 0.84 | PTGER1 (0.64) | PTGER1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL4168450 | 0.83 | PTGER1 (0.71) | PTGER1KMT2A | |
| SCHEMBL14008100 | 0.83 | PTGER1 (0.62) | PTGER1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4924558 | 0.83 | PTGER1 (0.67) | PTGER1ALDH1A1NPC1LMNARAB9A | |
| SCHEMBL4923076 | 0.83 | PTGER1 (0.76) | PTGER1HPGD | |
| SCHEMBL4924180 | 0.82 | PTGER1 (0.71) | PTGER1KMT2A | |
| SCHEMBL4926526 | 0.82 | PTGER1 (0.71) | PTGER1KMT2A | |
| SCHEMBL12563138 | 0.82 | HPGD (0.67) | KMT2AALDH1A1ALOX15NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885KMT2A 3116/4885ALDH1A1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.